Biomarkers for Monitoring Clinical Efficacy of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Allergic Asthma: an EAACI Position Paper.
Allergy. 2017 Feb 2. doi: 10.1111/all.13138. [Epub ahead of print]
Shamji MH1,2,3, Kappen JH1,2,4,3, Akdis M5, Jensen-Jarolim E6,7, Knol EF8, Kleine-Tebbe J9, Bohle B10, Chaker AM11,12, Till SJ13, Valenta R14, Poulsen LK15, Calderon MA1,2,3, Demoly P16, Pfaar O17, Durham LJ1,2,3, Schmidt-Weber CB11,12.
Abstract
Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma (1-12). AIT has disease modifying properties and confers long-term clinical benefit after cessation of treatment (6, 7, 13-17). AIT is routinely used in daily practice and can be administered either subcutaneously (SCIT) or sublingually (SLIT) (3-12).
Although AIT is effective, the degree of remission strongly varies depending on the complex interaction between patient, allergy, symptomatology and vaccines used for AIT (3-9). Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be significantly enhanced if there were means to identify those who are most likely to respond, when to stop treatment, how to predict relapse and when to perform booster AIT. Furthermore, biomarkers in AIT can play a central role in personalized medicine (18).
No comments:
Post a Comment